History

2012

June - Announced Strong Survival Results for first GLP NHP study with Entolimod (CBLB502)
March - Dosed first advanced cancer patient with Entolimod (CBLB502)

September - Launched Panacela Labs, Inc.
August - Science Translational Medicine published breakthrough paper on mechanisms of action of Curaxins

November - Dosed first advanced cancer patient with CBL0102 in Russian Federation
November - Granted Orphan Drug status designation by FDA for Entolimod (CBLB502)
September - Received second major development and conditional purchase contract for Entolimod (CBLB502) from CBMS/DoD
July - Granted Fast Track status designation by FDA for Entolimod (CBLB502)
April - Launched Incuron, LLC
January - Received first European patent for Entolimod (CBLB502)
January - Received first U.S. patent for Entolimod (CBLB502)

November - Entered licensing agreement for CBLB612 with Zhejiang Hisun Pharmaceutical Co. Ltd. In China
September - Awarded prestigious Grand Opportunities grant from NIAID/NIH

December - Completed first Phase II study of CBL0102 in Hormone Refractory Cancer Patients
October - Dosed first healthy volunteer in initial safety study with Entolimod (CBLB502)
September - Awarded first major development contract for Entolimod (CBLB502) from BARDA/DHHS
August - Opened IND for Entolimod (CBLB502) radiation countermeasure application
April - Science magazine published breakthrough paper on Entolimod (CBLB502)'s radioprotective activity
March - Awarded first major development contract for Entolimod (CBLB502) from CBMS/DoD

November - Completed first cGMP manufacturing run for Entolimod (CBLB502)
June - Formed strategic alliance with Roswell Park Cancer Institute and relocated to Buffalo, NY

June - IPO on NASDAQ
May - Opened IND for CBL0102 in US
2004-2006 - Received significant Small Business Innovation Research grant and contract funding from NASA and NIH

August - Established Cooperative Research and Development Agreement with Armed Forces Radiobiology Research Institute